Exelixis, Inc. (NASDAQ:EXEL) CMO Sells $3,309,124.72 in Stock

Exelixis, Inc. (NASDAQ:EXEL) CMO Amy C. Peterson sold 72,776 shares of the business’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the sale, the chief marketing officer now owns 465,393 shares of the company’s stock, valued at approximately $21,161,419.71. This represents a 13.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Exelixis Trading Down 1.9%

NASDAQ:EXEL opened at $45.40 on Monday. The company has a market cap of $12.51 billion, a PE ratio of 25.65, a P/E/G ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $48.85. The company’s 50 day moving average is $37.23 and its two-hundred day moving average is $35.84.

Analyst Ratings Changes

Several research firms have recently commented on EXEL. Stifel Nicolaus boosted their price target on shares of Exelixis from $36.00 to $38.00 and gave the company a “hold” rating in a report on Wednesday, May 14th. Barclays boosted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Citigroup boosted their price objective on shares of Exelixis from $45.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group reiterated an “underperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Finally, Truist Financial boosted their price objective on shares of Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.76.

Institutional Trading of Exelixis

Several large investors have recently bought and sold shares of EXEL. Coppell Advisory Solutions LLC purchased a new stake in Exelixis during the 4th quarter worth approximately $25,000. Hemington Wealth Management boosted its holdings in shares of Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 522 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 765 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of Exelixis in the 4th quarter valued at $32,000. Finally, Principal Securities Inc. boosted its holdings in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.